Skip to main content

Advertisement

Fig. 1 | BMC Cancer

Fig. 1

From: Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivo

Fig. 1

CDH11 is an independent prognosticator of poor clinical outcome and a regulator of the metastatic phenotype in breast cancer. a Analysis of GEO database showed that CDH11 mRNA level was approximately 2.5 folds higher in the invasive breast cancer cells (N = 389) than the normal breast tissues (N = 61). Kaplan-Meier plots showing (b) worse overall survival in patients with high CDH11 expression compared to the low expression group from analysis of TCGA breast invasive carcinoma cohort (n = 502), (c) high CDH expression confer shorter relapse-free survival, compared to the low expression group from the Desmedt-GSE7390 cohort (n = 198), and (d) the metastasis-free survival was worse in the high CDH11 group compared to the low group from the Kao Huang Breast GSE20685 cohort (n = 327). e PathwayNet network prediction of the functional connection of CDH11 with β-catenin, vimentin, FYN, CD44, EGFR, PRKCA and PRKCB

Back to article page